Amgen wins U.S. patent battle on arthritis drug Enbrel, thwarting Novartis

A U.S. judge on Friday said two patents relating to Amgen Inc's blockbuster rheumatoid arthritis drug Enbrel were valid, denying a challenge by Novartis AG, which is seeking to launch a copycat version.